The Power of Radiotherapy

The Specificity of Molecular Targeting

for Better
Patient Outcomes

Because Cancer Patients
Need a New Approach

Commitment

Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic  identifies the patients with the corresponding molecular signature who are the best candidates for therapy.

commitment

Targeted Therapies
for Personalized Medicine

Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.

News & Events

Andarix Pharmaceuticals to Present at Chinese Biopharmaceutical Association Conference, USA

Jul 18, 2018

Expanding Opportunities in Asia SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018…

Read More

Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Feb 12, 2018

Personalized Medicine for Small Cell Lung Cancer SOMERVILLE, Mass.— January 29, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018. The conference will focus…

Read More

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting

Feb 9, 2018

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —January 8, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of…

Read More